Loading...
Market
Total revenue generated by Leqembi in China in 2024
5
Resolution / Starting Odds
Below USD 100 million • 25%
USD 100 million to USD 200 million • 25%
USD 200 million to USD 300 million • 25%
Above USD 300 million • 25%
Official financial reports from Eisai/Biogen
Story
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China at USD24,800 per Year
Jun 27, 2024, 11:37 PM
Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, marking the third country after the United States and Japan to approve the drug. The treatment, which was approved by the Chinese regulator in January, is expected to be put into clinical use in Chinese hospitals, according to a hospital staffer in Shanghai. Leqembi, also known as Lecanemab, will cost CNY180,000 (USD24,800) per one-year cycle. This development signifies a significant step in the availability of advanced Alzheimer's treatments in China.
View original story
Similar markets
More than $500 million • 25%
$300 million to $500 million • 25%
$100 million to $300 million • 25%
Less than $100 million • 25%
More than $3 billion • 25%
Less than $2 billion • 25%
$2 billion - $2.5 billion • 25%
$2.5 billion - $3 billion • 25%
Less than $10 billion • 25%
$10 billion to $20 billion • 25%
$20 billion to $30 billion • 25%
More than $30 billion • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
< $500 million • 33%
$500 million - $1 billion • 33%
> $1 billion • 34%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $100 billion • 25%
$100 billion to $120 billion • 25%
$120 billion to $140 billion • 25%
More than $140 billion • 25%
Revenue increases • 25%
Revenue decreases • 25%
Revenue remains stable • 25%
Other • 25%
Less than 100,000 units • 25%
100,000 to 120,000 units • 25%
120,001 to 140,000 units • 25%
More than 140,000 units • 25%
Below $3 billion • 25%
$3 billion - $3.5 billion • 25%
$3.5 billion - $4 billion • 25%
Above $4 billion • 25%
More than $300 million • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than USD 1 billion • 25%
USD 500 million to USD 1 billion • 25%
USD 100 million to USD 500 million • 25%
Less than USD 100 million • 25%